• WedgePower of One — Novartis consolidated global creative + media to Publicis Groupe in 2018 (with creative led by Publicis Health and media led by Publicis Media). One of the LARGEST and most strategic pharma AOR consolidations of the decade. Renewed/confirmed multiple times since.
• WhyMNC pharma majors in TW competing with Novartis: Pfizer, Roche, MSD, AstraZeneca, Sanofi, Lilly, BMS, AbbVie. In cardiovascular: AstraZeneca (Brilinta, Forxiga), BI/Lilly (Jardiance), Bayer (Xarelto). In oncology: Roche, AstraZeneca, MSD (Keytruda), Pfizer. In psoriasis/immunology: AbbVie (Skyrizi, Rinvoq), J&J (Stelara, Tremfya), Lilly (Taltz). Local generics threat: Sandoz (now independent), TTY Biopharm (4105) for cardiovascular generics post-Entresto LOE.

1. W1Power of One — Novartis consolidated global creative + media to Publicis Groupe in 2018 (with creative led by Publicis Health and media led by Publicis Media). One of the LARGEST and most strategic pharma AOR consolidations of the decade. Renewed/confirmed multiple times since.
2. W2Sandoz spin-off (Oct 2023) means Novartis is now pure innovative-medicines — clearer creative narrative around 'Reimagining Medicine' breakthrough science
3. W3Entresto patent expiry pressure in major markets (US LOE 2025-2027) — peak commercialization window in Taiwan now
4. W4Pluvicto Taiwan launch / NHI reimbursement is the largest new launch wave — radioligand therapy is a category Novartis pioneered
5. W5Cosentyx is now facing biosimilar/IL-23 competition (Skyrizi from AbbVie, Tremfya from J&J) — defensive creative work expected

• MNC pharma majors in TW competing with Novartis: Pfizer, Roche, MSD, AstraZeneca, Sanofi, Lilly, BMS, AbbVie. In cardiovascular: AstraZeneca (Brilinta, Forxiga), BI/Lilly (Jardiance), Bayer (Xarelto). In oncology: Roche, AstraZeneca, MSD (Keytruda), Pfizer. In psoriasis/immunology: AbbVie (Skyrizi, Rinvoq), J&J (Stelara, Tremfya), Lilly (Taltz). Local generics threat: Sandoz (now independent), TTY Biopharm (4105) for cardiovascular generics post-Entresto LOE.
• VERY LOW. Novartis is one of Publicis Groupe's flagship 'Power of One' wins (2018) — full global integration across creative (Publicis Health), media (Publicis Media), data (Epsilon), and production. The mandate was specifically structured to LOCK OUT competing holding groups at the global level. WPP (Ogilvy Health, GroupM Health, VML Health) lost this seat and has effectively no central pharma marketing relationship with Novartis globally. In Taiwan: Publicis Health (Saatchi Wellness, Digitas Health, Razorfish Health) cascade through Asia Pacific. WPP would need to win at therapy-area or specific brand-team level — very narrow wedges. The deep Publicis Power-of-One infrastructure means even brand-level pitches face structural resistance.
• Entresto NHI pricing/coverage renewal cycles
• Pluvicto NHI reimbursement decision
• Cosentyx defensive campaign waves vs Skyrizi/Tremfya/Taltz competition
• Novartis Taiwan Country President changes (commercial restructuring trigger)
• Patient-association partnership announcements (Heart Failure Society, Psoriasis Assoc, MS Taiwan)
• Global Novartis quarterly earnings — innovative-medicines DTC spend disclosures

• Country President / General Manager Novartis Taiwan — incumbent unverifiedCountry President / GM Novartis Taiwan

  since

  Country President seat rotates ~3-4 years; current incumbent confirmation requires LinkedIn / press diligence. Reports to Novartis Asia AMAC regional president.

  Source ↗
• Therapy-Area Brand Heads (CRM, Oncology, IHD, Neuroscience)BU Brand Director — Novartis Taiwan

  since

  Day-to-day agency relationships sit with BU brand directors. Highest priority for any agency relationship-building: Cardiovascular (Entresto), Oncology (Kisqali/Pluvicto), and Immunology (Cosentyx) leads.

  Source ↗

Novartis Taiwan is a top-5 MNC pharma in Taiwan, established 1996 via merger of Ciba-Geigy and Sandoz operations. Post-Sandoz spin-off (Oct 2023), Novartis Taiwan is PURE-PLAY innovative medicines (Rx only). Heavy concentration in cardiovascular (Entresto is one of the top-selling Rx drugs in Taiwan NHI reimbursement), oncology radioligand therapy (Pluvicto/Lutathera — new growth platform), and immunology (Cosentyx). Taiwan Rx DTC is RESTRICTED under Pharmaceutical Affairs Act 藥事法 Article 66 — Rx promotion limited to HCPs only. Consumer spend is therefore (a) corporate brand campaigns, (b) unbranded disease-awareness (heart failure awareness, psoriasis awareness, MS Day), (c) patient association partnerships (中華民國心臟衰竭學會, Taiwan Psoriasis Association, MS Taiwan Society), (d) HCP digital + medical congress sponsorship. Estimated mid-tier ad spend (NT$200-400M).

No campaigns surfaced in research.

No decision-makers identified.

Novartis Taiwan reports into Novartis Asia, Middle East & Africa (AMAC) region — Singapore hub. Country President for Taiwan changes periodically; commercial structure is split by business unit: Cardiovascular-Renal-Metabolic (CRM), Oncology, Immunology-Hepatology-Dermatology (IHD), Neuroscience. Each BU has its own brand team with separate agency partners. Novartis Global Innovation pipeline coordinates from Basel HQ.